+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Infectious Disease Therapeutics Market by Drug Class (Antibiotics, Antifungals, Antivirals), Route Of Administration (Inhalation, Intravenous, Oral), Indication, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Infectious Disease Therapeutics Market by Drug Class (Antibiotics, Antifungals, Antivirals), Route Of Administration (Inhalation, Intravenous, Oral), Indication, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Infectious Disease Therapeutics Market by Drug Class (Antibiotics, Antifungals, Antivirals), Route Of Administration (Inhalation, Intravenous, Oral), Indication, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888743
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The infectious disease therapeutics market is advancing amid heightened demand for innovative treatments, rapidly shifting regulatory frameworks, and increasing global health challenges. Senior executives face a complex landscape where breakthrough science, evolving public health needs, and supply chain strategies shape opportunity and risk.

Market Snapshot: Infectious Disease Therapeutics Market

The Infectious Disease Therapeutics Market grew from USD 121.27 billion in 2024 to USD 126.80 billion in 2025. It is expected to continue growing at a CAGR of 4.43%, reaching USD 157.36 billion by 2030. This upward trajectory is propelled by scientific advances, clinical adoption across various drug classes, and the convergence of digital health and manufacturing innovations. Stakeholders must adapt to emerging partnerships and shifting regulatory pathways that are accelerating the journey from research to patient delivery. As new resistance patterns and global emergencies become more frequent, the market rewards agility and forward-looking investment in strategic ecosystems.

Scope & Segmentation

  • Drug Classes: Includes antibiotics (aminoglycosides, beta lactams, fluoroquinolones, macrolides, tetracyclines), antifungals (azoles, echinocandins, polyenes), antivirals (integrase inhibitors, neuraminidase inhibitors, nucleoside analogues, protease inhibitors), biologics (cytokines, monoclonal antibodies), and vaccines (conjugate, inactivated, live attenuated, subunit).
  • Administration Routes: Encompasses inhalation, intravenous, oral, and topical options to address varied patient and treatment needs.
  • Indications: Covers COVID-19, gastrointestinal, hepatitis, HIV/AIDS, respiratory, skin, and urinary tract infections, reflecting broad therapeutic demand.
  • Distribution Channels: Ranges from hospital pharmacy, online, and retail channels for seamless product access.
  • End User Groups: Includes clinics, homecare providers, and hospitals impacting care models and delivery pathways.
  • Regional Coverage: Spans Americas (with focus markets including United States, Canada, Brazil, Mexico, Argentina), Europe, the Middle East & Africa (such as United Kingdom, Germany, France, Russia, regional leaders, and emerging markets), and Asia-Pacific (China, India, Japan, Australia, and regionally significant economies).
  • Corporate Profiles: Analyzes strategic moves by Pfizer Inc., Gilead Sciences, Johnson & Johnson, F. Hoffmann-La Roche, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, AbbVie, Novartis, and others shaping the sector.

Key Takeaways for Decision-Makers

  • Platform technologies and precision approaches are redefining therapeutic development, enabling targeted treatments and faster pathway to market.
  • Collaborative frameworks among academia, industry consortia, and public health bodies are accelerating innovation and de-risking early-stage investment.
  • Regulatory evolution is expediting approval processes, yet demands robust stewardship and adaptive clinical strategies to ensure ongoing safety and relevance.
  • Supply chain resilience is now central, with regional hubs and dual-sourcing strategies mitigating risks from geopolitical and tariff-induced disruptions.
  • Digital health technologies, including artificial intelligence for candidate screening, are fostering efficiency and enabling rapid clinical adaptation to emerging threats.
  • Region-specific dynamics drive adoption rates, with developed and emerging areas balancing access, local manufacturing policies, and infrastructure investments.

Tariff Impact: 2025 U.S. Trade Dynamics

Recent U.S. tariff enforcement is catalyzing significant supply chain realignment. Manufacturers face higher input costs that drive sourcing changes and investment in domestic capacity. Organizations are establishing regional manufacturing clusters and forging long-term partnerships to enhance resilience. These tariff changes are also prompting distributors and procurement teams to seek risk-sharing agreements and diversify supplier networks, ensuring continued access amid global trade shifts.

Methodology & Data Sources

This report employs a multi-method approach, combining deep secondary research with structured primary interviews across R&D, procurement, clinical, and economic domains. Quantitative insights are validated through triangulation of diverse data streams, supported by scenario planning for tariff shifts and regulatory reforms. Geospatial analysis and peer review ensure findings are robust and actionable for senior leaders.

Why This Report Matters

  • Equips senior executives with actionable insights to inform portfolio planning, R&D prioritization, and strategic partnerships in a complex market environment.
  • Clarifies the effect of tariff and regulatory changes on supply chains, guiding risk mitigation and capacity expansion decisions.
  • Highlights innovation opportunities across therapeutic classes, distribution channels, and regions—supporting evidence-based investment and resource allocation.

Conclusion

This analysis provides a strategic lens to interpret cross-market trends and operational imperatives in infectious disease therapeutics. Leaders who leverage data-driven insights and adaptive frameworks will be best positioned for sustainable growth and impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Accelerated development of mRNA-based vaccines for seasonal and emerging respiratory virus prevention
5.2. Increased adoption of long-acting monoclonal antibodies for prophylaxis in immunocompromised COVID-19 patients
5.3. Integration of CRISPR-based rapid diagnostics with bespoke antibiotic stewardship in tertiary care hospitals
5.4. Clinical advancement of broad-spectrum viral polymerase inhibitors for pandemic respiratory pathogen readiness
5.5. Emergence of oral direct-acting antivirals targeting hepatitis delta co-infection in chronic hepatitis B regimes
5.6. Innovation in host-directed therapies aiming to modulate innate immunity and reduce sepsis-related mortality
5.7. Engineering synthetic antimicrobial peptides to overcome multidrug-resistant bacterial infections in clinical trials
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Infectious Disease Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Antibiotics
8.2.1. Aminoglycosides
8.2.2. Beta Lactams
8.2.3. Fluoroquinolones
8.2.4. Macrolides
8.2.5. Tetracyclines
8.3. Antifungals
8.3.1. Azoles
8.3.2. Echinocandins
8.3.3. Polyenes
8.4. Antivirals
8.4.1. Integrase Inhibitors
8.4.2. Neuraminidase Inhibitors
8.4.3. Nucleoside Analogues
8.4.4. Protease Inhibitors
8.5. Biologics
8.5.1. Cytokines
8.5.2. Monoclonal Antibodies
8.6. Vaccines
8.6.1. Conjugate
8.6.2. Inactivated
8.6.3. Live Attenuated
8.6.4. Subunit
9. Infectious Disease Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Inhalation
9.3. Intravenous
9.4. Oral
9.5. Topical
10. Infectious Disease Therapeutics Market, by Indication
10.1. Introduction
10.2. COVID-19
10.3. Gastrointestinal Infections
10.4. Hepatitis
10.5. HIV/AIDS
10.6. Respiratory Infections
10.7. Skin Infections
10.8. Urinary Tract Infections
11. Infectious Disease Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Infectious Disease Therapeutics Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare
12.4. Hospitals
13. Americas Infectious Disease Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Infectious Disease Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Infectious Disease Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Gilead Sciences, Inc.
16.3.3. Johnson & Johnson
16.3.4. F. Hoffmann-La Roche Ltd
16.3.5. Merck & Co., Inc.
16.3.6. GlaxoSmithKline plc
16.3.7. Sanofi S.A.
16.3.8. AstraZeneca plc
16.3.9. AbbVie Inc.
16.3.10. Novartis AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. INFECTIOUS DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. INFECTIOUS DISEASE THERAPEUTICS MARKET: RESEARCHAI
FIGURE 26. INFECTIOUS DISEASE THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 27. INFECTIOUS DISEASE THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 28. INFECTIOUS DISEASE THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. INFECTIOUS DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 153. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 154. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 155. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 156. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 157. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
TABLE 158. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2030 (USD MILLION)
TABLE 159. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 160. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 161. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 162. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 163. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 164. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 165. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 168. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 169. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 176. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 177. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
TABLE 178. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2030 (USD MILLION)
TABLE 179. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 180. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 181. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 182. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 183. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 184. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 185. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 188. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 189. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 276. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 277. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 278. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 279. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
TABLE 280. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2030 (USD MILLION)
TABLE 281. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 282. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 283. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 284. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 285. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 286. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 287. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 290. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 291. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 296. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 297. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 298. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 299. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
TABLE 300. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Infectious Disease Therapeutics market report include:
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • AstraZeneca plc
  • AbbVie Inc.
  • Novartis AG

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 126.8 Billion
Forecasted Market Value ( USD ) by 2030 $ 157.36 Billion
Compound Annual Growth Rate4.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Infectious Disease Therapeutics Market Size, Share & Trends Analysis Report By Infection (Bacterial, Viral), By Drug Class (Antibacterial, Antiviral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Infectious Disease Therapeutics Market Size, Share & Trends Analysis Report By Infection (Bacterial, Viral), By Drug Class (Antibacterial, Antiviral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Infectious Disease Therapeutics Market Report and Forecast 2025-2034 - Product Image

Infectious Disease Therapeutics Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Infectious Disease Therapeutics - Global Strategic Business Report - Product Image

Infectious Disease Therapeutics - Global Strategic Business Report

  • Report
  • 385 Pages
  • Global
From
Infectious Disease Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Infectious Disease Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 140 Pages
  • Global
From
Infectious Disease Therapeutics Market Report 2025 - Product Image

Infectious Disease Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Infectious Disease Drug Market

The Infectious Disease Drug market is a subset of the pharmaceutical industry that focuses on the development and production of drugs to treat infectious diseases. These drugs are used to treat a wide range of illnesses, from bacterial and viral infections to fungal and parasitic diseases. The market is highly competitive, with many companies vying for market share. Companies in the market are typically focused on developing new drugs, as well as improving existing treatments. They also work to ensure that their drugs are safe and effective. Some of the major players in the Infectious Disease Drug market include Pfizer, Merck, GlaxoSmithKline, Sanofi, Johnson & Johnson, and AstraZeneca. These companies are involved in the research, development, and production of drugs to treat a variety of infectious diseases. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.